Sinotau Pharmaceutical Group
Clinical trials sponsored by Sinotau Pharmaceutical Group, explained in plain language.
-
New heart scan agent aims to spot dangerous blockages more accurately
Diagnosis Recruiting nowThis study tests whether a new injection called XTR004, used during a PET heart scan, can better identify significant blockages in the heart's arteries compared to standard scans. About 395 adults with known or suspected stable coronary artery disease will receive the injection a…
Phase: PHASE3 • Sponsor: Sinotau Pharmaceutical Group • Aim: Diagnosis
Last updated May 17, 2026 00:45 UTC
-
New scan could help doctors decide who needs heart surgery
Diagnosis Recruiting nowThis study tests a new imaging method (XTR003 injection with a standard PET scan) to see which parts of the heart are still alive in people with heart failure due to blocked arteries. About 40 to 60 adults with weak hearts will get this scan, then have heart surgery to restore bl…
Phase: PHASE2 • Sponsor: Sinotau Pharmaceutical Group • Aim: Diagnosis
Last updated May 13, 2026 16:03 UTC
-
New imaging tracer for prostate cancer tested in healthy adults
Diagnosis Recruiting nowThis early-stage study tests a new imaging drug called Flotufolastat F-18 in 6 healthy Chinese adults. The drug is a radioactive tracer that helps spot prostate cancer cells on PET scans. The goal is to check its safety, how it spreads in the body, and the radiation dose received…
Phase: PHASE1 • Sponsor: Sinotau Pharmaceutical Group • Aim: Diagnosis
Last updated May 07, 2026 18:40 UTC